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Abstract: INTRODUCTION Several high quality randomized controlled studies were recently published
on non-vitamin K oral anticoagulants (NOACs) in patients with or at risk for coronary artery (CAD) or
peripheral artery disease (PAD). While a reduction on cardiovascular event is known and an increase in
moderate bleeding is expected, the effect of this strategy on survival is currently unknown. Accordingly,
we performed a comprehensive systematic review and meta-analysis of randomized controlled trials to
investigate the effect of NOAC on survival. EVIDENCE ACQUISITION We searched Pubmed, EM-
BASE, Cochrane Central Register, and Clinicaltrials.gov (last updated March 31st 2019). The primary
endpoint was all-cause mortality at the longest reported follow-up. Coprimary endpoint was major bleed-
ing according to the International Society on Thrombosis and Hemostasis (ISTH) criterion. EVIDENCE
SYNTHESIS We included ten randomized controlled trials comparing NOACs versus control treatment
(placebo, single platelet or dual antiplatelet therapy) enrolling 66665 patients with or at risk for CAD
or PAD. NOACs were associated with a decreased risk of mortality (825/41655 [4.4%] versus 405/25010
[5.6%] RR 0.93 [95% CI: 0.87-1.00], P=0.04), and an increased risk for major bleeding (RR 1.62 [95%
CI: 1.23-2.13], P=0.0005) when compared to control. Findings were robust to trial sequential, subgroup,
and sensitivity analyses. Low doses NOACs were associated with a reduced mortality when compared to
standard dose NOACs. CONCLUSIONS NOACs reduced all-cause mortality in patients with or at risk
for CAD or PAD, even though they increased the risk of major bleeding. Future studies regarding the
best doses of NOACs are warranted.
DOI: https://doi.org/10.23736/S0026-4725.19.05043-6
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a B S T r a C T
iNTrodUCTioN: Several high quality randomized controlled studies were recently published on non-vitamin K oral 
anticoagulants (NoaCs) in patients with or at risk for coronary artery (Cad) or peripheral artery disease (Pad). While 
a reduction on cardiovascular event is known and an increase in moderate bleeding is expected, the effect of this strategy 
on survival is currently unknown. accordingly, we performed a comprehensive systematic review and meta-analysis of 
randomized controlled trials to investigate the effect of NoaC on survival.
eVideNCe aCQUiSiTioN: We searched Pubmed, eMBaSe, Cochrane Central register, and Clinicaltrials.gov (last 
updated March 31th 2019). The primary endpoint was all-cause mortality at the longest reported follow-up. Coprimary 
endpoint was major bleeding according to the international Society on Thrombosis and Hemostasis (iSTH) criterion.
eVideNCe SYNTHeSiS: We included ten randomized controlled trials comparing NoaCs versus control treatment 
(placebo, single platelet or dual antiplatelet therapy) enrolling 66665 patients with or at risk for Cad or Pad. NoaCs 
were associated with a decreased risk of mortality (825/41655 [4.4%] versus 405/25010 [5.6%] rr 0.93 [95% Ci: 0.87-
1.00], P=0.04), and an increased risk for major bleeding (rr 1.62 [95% Ci: 1.23-2.13], P=0.0005) when compared to 
control. Findings were robust to trial sequential, subgroup, and sensitivity analyses. low doses NoaCs were associated 
with a reduced mortality when compared to standard dose NoaCs.
CoNClUSioNSː NoaCs reduced all-cause mortality in patients with or at risk for Cad or Pad, even though they 
increased the risk of major bleeding. Future studies regarding the best doses of NoaCs are warranted.
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Introduction
Cardiovascular diseases are one of the lead-ing causes of morbidity and mortality 
worldwide with coronary artery (Cad) and pe-
ripheral artery diseases (Pad) representing the 
main burden for patients and national health 
systems.1 Non-vitamin K antagonist oral anti-
coagulants (NoaC) were developed for being 
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Evidence acquisition
We performed a systematic review and meta-
analysis of randomized controlled trials (rCTs), 
according to the Cochrane methodology13 and 
preferred reporting items for systematic reviews 
and meta-analyses PriSMa.14
Search strategy and selection criteria
Two trained investigators (aN, JHK) indepen-
dently searched Pubmed, eMBaSe, and the Co-
chrane Central register of clinical trials together 
with Clinicaltrials.gov for recently completed 
but not published studies, dated up to March 
31th, 2019. The search strategies for PubMed and 
eMBaSe are available in the Supplementary 
digital Material 1 (Supplementary Text File 1). 
The search strategies were designed to find any 
rCTs ever published with the utilization of No-
aCs in patients with or at risk for Cad or Pad. 
We checked the references of included studies to 
identify more eligible rCTs. No language restric-
tions were added. articles were first screened as 
title and abstract and, if met the inclusion crite-
ria, retrieved as a complete manuscript. eligible 
studies had to meet the following PiCoS crite-
ria: Population: adult patients with the diagnosis 
or at high risk of Cad or Pad; interventions: 
administration of NoaCs and antiplatelet drugs 
or NoaCs alone; Comparison intervention: 
placebo or single or dual antiplatelet therapy; 
outcome: survival, or occurrence of clinically 
significant bleeding; Study design: randomized 
controlled trials. disagreements between the two 
investigators about the eligibility of the article 
were solved by a third expert author.
Data analysis
Two trained authors (aN, JHK) separately gath-
ered the baseline characteristics, outcome data, 
and additional relevant information from the 
selected studies. The primary endpoint was all 
cause of mortality at the longest reported follow-
up. Coprimary endpoint was major bleeding ac-
cording to the international Society on Throm-
bosis and Hemostasis (iSTH) criterion.15 Sec-
ondary endpoints were the rate of cardiovascular 
death, acute myocardial infarction, hemorrhagic 
and non-hemorrhagic stroke, fatal bleeding, in-
lants, with a more practical profile, such as oral 
administration with no need for routine moni-
toring or dose adjustment. NoaCs are factor 
Xa or direct thrombin inhibitors. Ximelagatran 
was the first one, had limited success, but set 
the stage for the four widely approved and used 
NoaCs: dabigatran, rivaroxaban, apixaban, 
and edoxaban. guidelines are already includ-
ing NoaCs in the prevention of stroke in atrial 
fibrillation (except for the patients with me-
chanical prosthetic valves, or moderate to se-
vere mitral stenosis),2 in the prevention or treat-
ment of venous thromboembolism (VTe) after 
elective total hip or knee replacement surgery 
or in case of recurrent VTe.2, 3 atherosclerosis 
is the common underlying pathophysiology in 
stable or unstable Cad or Pad.1 an eroded or 
ruptured plaque can activate both platelet ag-
gregation and the coagulation cascade, leading 
to a thrombus or embolism.1 Unsurprisingly, 
atherosclerosis is associated with a high risk of 
cardiovascular adverse events and death. aspi-
rin inhibits platelet aggregation, reduces vas-
cular events risk and mortality and is therefore 
widely used in primary and secondary cardio-
vascular prevention.1, 4, 5 additional P2Y12 in-
hibitor treatment offers a better survival in pa-
tients with recent acute myocardial infarction.4 
However, despite the single or dual antiplatelet 
therapy, the number of new or recurrent car-
diovascular adverse events including death is 
considerably high.6 of note, there is no recom-
mendation in guidelines (e.g. american Heart 
association, european Society of Cardiology) 
against or towards the use of NoaCs in this pa-
tient population. Published meta-analyses com-
pared NoaCs to vitamin K antagonist drugs 
in atrial fibrillation,7-9 investigated NoaCs in 
addition to single or dual antiplatelet therapy 
in acute coronary syndrome (aCS),10 focused 
on patients with ischemic heart disease11 and 
explored the role of rivaroxaban in Cad.12 
results are contradictory and there is lack of 
a comprehensive meta-analysis on this impor-
tant field. The aim of our systematic review and 
meta-analysis is to evaluate the effect of No-
aCs versus placebo or single or dual antiplate-
let therapy on survival and bleeding in patients 
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day; apixaban 10 mg/day; dabigatran 220 mg/
day.16, 17 These drugs are used in various clini-
cal indications, therefore it was hard to create a 
threshold value between the two subgroups. We 
created these categories considering the dosages 
of the included studies and the international rec-
ommendations.
our study was preregistered in ProSPero 
(reg. No. 2019-Crd42019119717).
Evidence synthesis
our search strategy identified 761 records (Fig-
ure 1). Major exclusion papers are presented in 
Supplementary digital Material 2 (Supplemen-
tary Table i). Ten studies were eligible for inclu-
sion into the final analyses (Table i).4-6, 18-24
in summary, the data of 66,665 (41,655 exper-
imental and 25,010 control group) patients were 
included. The most commonly studied study drug 
was rivaroxaban (5 out of 10 studies4, 6, 20, 21, 24) 
followed by apixaban (3 studies18, 19, 22), and 
dabigatran (2 studies5, 23). The studied settings 
were recent aCS in 7 articles4, 18-23 and were 
stable Cad or Pad,6 myocardial injury after 
non-cardiac surgery (MiNS),5 and heart failure 
with Cad24 in each other articles. Placebo was 
used as control treatment in 8 studies,5, 18-24 the 
tracranial bleeding, gastrointestinal bleeding, 
minor bleeding and need for hospital admission. 
in case of missing data of an outcome of inter-
est, we contacted the corresponding authors. For 
the evaluation of the included trial risk of bias, 
we used the Cochrane methodology.13 We as-
sessed each study separately according to Co-
chrane’s seven items as low, high or unclear risk 
of bias. We performed our analysis with revMan 
5.3. software (review Manager, The Nordic 
Cochrane Centre, The Cochrane Collaboration, 
Copenhagen, denmark) and Stata version 14.1 
(StataCorp., College station, TX, USa). For di-
chotomous outcomes in primary and secondary 
endpoints, individual and pooled risk ratios were 
calculated via the Mantel-Haenszel method. We 
presented calculated risk ratio (rr) with 95% 
confidence intervals (Ci). all reported P values 
are two-sided and the values equal or less than 
0.05 were counted as significant. Heterogeneity 
among included studies was analyzed with Co-
chrane Q statistics and quantified with i2. Fixed 
effect model was performed to create meta-anal-
ysis in the absence of significant heterogeneity, 
defined as P value >0.10 and i2<40%.13 We em-
ployed a random-effect model in case of signifi-
cant heterogeneity. We performed a fixed-effects 
trial sequential analysis (TSa) with the intent of 
maintaining an overall 5% risk of type i error and 
a 20% risk of type ii error, at a power of 80%. 
We assumed a relative risk reduction of 15% and 
derived the control event proportion from the 
dataset. The resulting required information size 
was further diversity (d2)-adjusted. in the case 
of d2=0, we performed a sensitivity analysis as-
suming a d2=25%. The TSa Viewer software 
was used to perform TSa (TSa Viewer [Com-
puter program], version 0.9.5.5 Beta, Copenha-
gen Trial Unit, Centre for Clinical intervention 
research, rigshospitalet, 2016).
Based on Cochrane methodology, we per-
formed further subgroup analyses. in particular, 
we investigated the effect of low dose NoaCs 
and standard dose NoaCs. Subgroup differ-
ences were tested using χ2 statistics. We con-
sidered the following mg/day dosages as low 
dose: rivaroxaban 5 mg/day; apixaban 5 mg/day; 
dabigatran 100-150 mg/day. The following were 
considered standard dose: rivaroxaban 10 mg/
Figure 1.—Flow chart of study selection.
NoaCs: non-vitamin K oral anticoagulants; lMWH: low 
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Figure 2.—Forest plots of 
all-cause mortality at the 
longest follow-up.4-6, 18-24
NoaCs: non-vitamin K 
oral anticoagulants.
Table I.—Characteristics of included studies.
Study abbreviation Population Study period Patient etiology Type of NoaC Study groups NoaC patients Control atients
alexander et al. (2009)18 aPPraiSe 1691 2006.05-2007.10 recent aCS with high risk factors aPX 5 mg aPX /10 mg aPX / 20 mg aPX / Placebo 630 599
alexander et al. (2011)19 aPPraiSe-2 7392 2009.03-2010.11 recent aCS with high risk factors aPX 10 mg (5 mg in decreased renal function) aPX / Placebo 3705 3687
devereaux et al. (2018)5 MaNage trial 1754 2013.01-2017.07 Myocardial injury after non-cardiac surgery daBi 220 mg daBi / Placebo 877 877
eikelboom et al. (2017)6 CoMPaSS trial 27,395 2013.03-2016.05 Stable atherosclerotic vascular disease riV 5 mg riV + aSa / 10 mg riV / Placebo + aSa 18269 9126
Mega et al. (2009)20 aTlaS aCS-TiMi 46 3491 2006.11-2008.09 recent aCS riV 5, 10, 20 mg riV / 5, 10, 15, 20 mg riV + thienopyridine / Placebo 2331 1153
Mega et al. (2012)21 aTlaS aCS-TiMi 51 15,526 2008.11-2011.09 recent aCS riV 5 mg riV / 10 mg riV / Placebo 10229 5113
ogawa et al. (2013)22 aPPraiSe-Japan 149 2009.04-2010.11 recent aCS with high risk factors aPX 5 mg aPX / 10 mg aPX / Placebo 98 51
ohman et al. (2017)4 geMiNi-aCS-1 3037 2015.04-2016.10 after aCS riV 5 mg riV + P2Y12inhibitor / aSa + P2Y12inhibitor 1519 1518
oldgren et al. (2011)23 re-deeM 1861 2008.03-2009.10 recent Mi, and at high risk of new 
ischemia
daBi 100 mg daBi / 150 mg daBi / 220 mg daBi / 300 mg daBi / Placebo 1490 371
Zannad et al. (2018)24 CoMMaNder HF 5022 2013.09-2017.10 recent worsening heart failure, reduced eF, 
Cad, and no aF
riV 5 mg riV / Placebo 2507 2515
NoaC: non-vitamin K oral anticoagulant; aCS: acute coronary syndrome; eF: ejection fraction; Cad: coronary artery disease; aF: atrial 
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difference between treatment and control in case 
of low doses (7 rCT, 997/18974 [5.3%] NoaC, 
1136/19293 [5.9%] control, N.=38267, rr 0.85 
[95% Ci: 0.69-1.06], P=0.14, i2=71%) and also 
in case of standard doses (7 rCT, 776/19,584 
[4.0%] NoaC, 810/19,824 [4.1%] control, 
N.=39,408, rr 0.96 [95% Ci: 0.87-1.06], 
P=0.44, i2=0%) (Figure 2).
Major bleeding
Patients treated with NoaCs had an increased 
risk of major bleeding according to iSTH when 
compared to control group (8 rCT, 681/29,095 
[2.3%] NoaC, 327/18,744 [1.7%] control, 
N.=47,839, rr 1.62 [95% Ci: 1.23-2.13], 
P=0.0005, i2=60%) (Figure 3).4-6, 18-24 TSa anal-
ysis revealed this inconclusive (Supplementary 
digital Material 5: Supplementary Figure 2).
Comparison of different doses of NoaC re-
vealed, that standard dose significantly increased 
the risk of major bleeding (4 rCT, 216/10,253 
[2.1%] low dose, 271/9887 [2.7%] standard 
dose, N.=20,140, rr 0.78 [95% Ci: 0.66-0.93], 
P=0.007, i2=6%) (Supplementary digital Mate-
rial 6: Supplementary Table iii). Subgroup analy-
sis found that, both low dose (6 rCT, 329/14279 
[2.3%] NoaC, 244/14180 [1.7%] control, 
N.=28,459, rr 1.35 [95% Ci: 1.15-1.59], 
P=0.0003, i2=0%) and standard dose (6 rCT, 
428/14,469 [3.0%] NoaC, 260/14711 [1.8%] 
control, N.=29180, rr 1.66 [95% Ci: 1.43-1.93], 
P<0.0001, i2=38%) increased the risk of major 
bleeding compare to control treatment (Table ii).
remaining two4, 6 used aspirin. Standard medica-
tion of artery diseases was maintained during the 
study period, therefore none of the comparator 
groups were totally free of antiplatelet (aspirin 
and/or P2Y12 antagonists) treatment. only one 
study6 had an experimental arm without ad-
ministration of antiplatelet agents. eight stud-
ies4, 6, 18, 20-24 used a low dose and 8 studies5, 6, 18-23 
used a standard dose of NoaC. all studies had 
low risk of bias (Supplementary digital Material 
3: Supplementary Table ii).
Mortality
overall, administration of NoaCs significantly 
decreased the risk of death compared to control 
treatment (10 rCT, 1825/41,655 [4.4%] NoaC, 
1405/25,010 [5.6%] control, N.=66,665, rr 
0.93 [95% Ci: 0.87-1.00], P=0.04, i2=0%) (Fig-
ure 2).4-6, 18-24 Final analysis is conclusive ac-
cording to TSa (Supplementary digital Material 
4: Supplementary Figure 1).
overall, we found significant difference in the 
comparison of low dose versus standard dose of 
NoaCs (5 rCT, 429/14,948 [2.9%] low dose, 
521/15002 [3.5%] standard dose, N.=29,950, rr 
0.82 [0.73-0.93], P=0.002, i2=33%). Sequential 
removing each trial did not change magnitude 
and direction of treatment effect (lowest rr 0.81 
[95% Ci: 0.71-0.92], P=0.001, i2=0%) with the 
removal of alexander et al. and (highest rr 0.86 
[95% Ci: 0.74-0.99], P=0.04, i2=35%) with the 
removal of Mega et al. Subgroup analysis by 
low dose and standard dose of NoaCs found no 
Table I.—Characteristics of included studies.
Study abbreviation Population Study period Patient etiology Type of NoaC Study groups NoaC patients Control atients
alexander et al. (2009)18 aPPraiSe 1691 2006.05-2007.10 recent aCS with high risk factors aPX 5 mg aPX /10 mg aPX / 20 mg aPX / Placebo 630 599
alexander et al. (2011)19 aPPraiSe-2 7392 2009.03-2010.11 recent aCS with high risk factors aPX 10 mg (5 mg in decreased renal function) aPX / Placebo 3705 3687
devereaux et al. (2018)5 MaNage trial 1754 2013.01-2017.07 Myocardial injury after non-cardiac surgery daBi 220 mg daBi / Placebo 877 877
eikelboom et al. (2017)6 CoMPaSS trial 27,395 2013.03-2016.05 Stable atherosclerotic vascular disease riV 5 mg riV + aSa / 10 mg riV / Placebo + aSa 18269 9126
Mega et al. (2009)20 aTlaS aCS-TiMi 46 3491 2006.11-2008.09 recent aCS riV 5, 10, 20 mg riV / 5, 10, 15, 20 mg riV + thienopyridine / Placebo 2331 1153
Mega et al. (2012)21 aTlaS aCS-TiMi 51 15,526 2008.11-2011.09 recent aCS riV 5 mg riV / 10 mg riV / Placebo 10229 5113
ogawa et al. (2013)22 aPPraiSe-Japan 149 2009.04-2010.11 recent aCS with high risk factors aPX 5 mg aPX / 10 mg aPX / Placebo 98 51
ohman et al. (2017)4 geMiNi-aCS-1 3037 2015.04-2016.10 after aCS riV 5 mg riV + P2Y12inhibitor / aSa + P2Y12inhibitor 1519 1518
oldgren et al. (2011)23 re-deeM 1861 2008.03-2009.10 recent Mi, and at high risk of new 
ischemia
daBi 100 mg daBi / 150 mg daBi / 220 mg daBi / 300 mg daBi / Placebo 1490 371
Zannad et al. (2018)24 CoMMaNder HF 5022 2013.09-2017.10 recent worsening heart failure, reduced eF, 
Cad, and no aF
riV 5 mg riV / Placebo 2507 2515
NoaC: non-vitamin K oral anticoagulant; aCS: acute coronary syndrome; eF: ejection fraction; Cad: coronary artery disease; aF: atrial 
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tal Material 8 (Supplementary Table iV). eg-
ger’s test revealed publication bias in the minor 
bleeding analysis (P=0.035) (Table ii, Supple-
mentary digital Material 9: Supplementary Fig-
ure 4), the remaining analyses are free of pub-
lication bias (Table ii, Supplementary digital 
Material 9).
Limitations of the study
one limitation of our study is that we included 
studies which used a different definition of ma-
jor bleeding. The majority of studies used iSTH 
definition of major bleeding, but some of the 
studies used TiMi definition20, 21 and after un-
successful attempts to contact the authors we 
excluded those studies from this outcome anal-
Secondary outcomes
Meta-analyses of secondary outcomes revealed 
the following results. The risk rate of cardio-
vascular death, acute myocardial infarction, and 
stroke (hemorrhagic and non-hemorrhagic) was 
significantly higher in the control group com-
pared to NoaC treatment group. The risk of 
intracranial bleeding, gastrointestinal bleeding, 
and minor bleeding was increased among pa-
tients treated with NoaCs compare to control 
(Table ii, Supplementary digital Material 7: 
Supplementary Figure 3).
Sensitivity analysis performed by sequential 
removal of each included study did not change 
the magnitude and direction of the overall re-
sults and are reported in Supplementary digi-
Figure 3.—Forest plots of 
major bleeding according 
to international Society on 
Thrombosis and Hemosta-
sis (iSTH).4-6, 18-24
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study used competing risk models (CrM) for the 
main analysis, and we also extracted raw event 
estimates. Therefore, CrM was not applied to 
our analysis either. While heterogeneity was 
mild for main comparative analyses, it varied 
substantially depending on outcome or control 
group, with more severe heterogeneity when ap-
praising endpoints with different definitions. Fi-
nally, no multivariate meta-analysis method was 
applied in our work.
Conclusions
our results show that NoaCs decrease all-cause 
mortality in Cad and Pad, but they also in-
crease the risk of major bleeding by iSTH crite-
ria. results were confirmed in most sub-analyses 
and sensitivity analyses.
The only recent meta-analysis of NoaCs 
ysis. Patients were at different risk profiles in 
the included trials, since we chose to involve a 
wide spectrum of diseases (although they shared 
same pathogenesis) in our population. The com-
prehensive range of disease could cause the sig-
nificant heterogeneity among the results of the 
trials. Two further limitation can be the distinc-
tion of different NoaC doses with creating low 
and standard dose and also the comparability of 
different type of NoaCs with low and standard 
doses. different concomitant antiplatelet thera-
pies were used in the included studies, therefore, 
our population is heterogenic in that aspect. The 
recruiting time of the first and last included study 
were more than 10 years apart, which could 
have caused changes in many aspects. another 
possible limitation of all the studies included in 
this meta-analysis is that they were all supported 
by pharmaceutical companies. Furthermore, no 

















valueevents Total events Total
all-cause mortality at 
longest follow-up
10 66,665 1825 41,655 1405 25,010 0.93 (0.87-1.00) 0.04 0 0.919
low dose 7 38,267 997 18,974 1136 19,293 0.85 (0.69-1.06) 0.14 71
Standard dose 7 39,408 776 19,584 810 19,824 0.96 (0.87-1.06) 0.44 0
Major bleeding (iSTH) 8 47,839 681 29,095 327 18,744 1.62 (1.23-2.13) 0.001 60 0.113
low dose 6 28,459 329 14,279 244 14,180 1.35 (1.15-1.59) <0.001 0
Standard dose 6 29,180 428 14,469 260 14711 1.66 (1.43-1.93) <0.001 38
Cardiovascular death 9 63,181 1251 39,324 1032 23,857 0.90 (0.84-0.99) 0.01 0 0.668
low dose 7 38,686 754 19,393 859 19,293 0.87 (0.71-1.06) 0.18 58
Standard dose 7 39,408 494 19,584 539 19,824 0.92 (0.82-1.04) 0.19 0
acute myocardial 
infarction
10 66,665 1227 41,655 905 25,010 0.88 (0.80-0.96) 0.003 0 0.559
low dose 7 38,686 561 19,393 624 19,293 0.90 (0.80-1.01) 0.07 0
Standard dose 7 39,408 591 19,584 694 19,824 0.86 (0.77-0.96) 0.006 0
Stroke 10 66,665 391 41,655 327 25,010 0.69 (0.53-0.91) 0.008 44 0.146
low dose 3 19,486 84 9938 146 9548 0.57 (0.44-0.74) <0.001 0
Standard dose 5 31,102 155 15,564 197 15,538 0.79 (0.64-0.97) 0.02 22
Fatal bleeding 7 60,198 67 37,817 29 22,381 1.37 (0.89-2.11) 0.15 0 0.529
low dose 6 37,772 32 19,078 29 18,694 1.07 (0.64-1.77) 0.80 0
Standard dose 6 39,961 44 19,269 35 20,692 1.63 (0.68-3.91) 0.28 60
intracranial bleeding 7 58,010 120 36,719 35 21,291 1.91 (1.31-2.77) 0.001 0 0.327
low dose 5 33,564 43 16,837 29 16,727 1.47 (0.92-2.35) 0.10 18
Standard dose 6 40,455 77 19,535 35 20,920 2.20 (1.48-3.28) <0.001 0
gastrointestinal bleeding 5 32,388 326 21,364 83 11,024 2.00 (1.57-2.54) <0.001 0 0.507
low dose 4 20,400 179 10,253 77 10,147 2.53 (1.31-4.91) 0.006 54
Standard dose 5 21,788 136 10,764 83 11,024 1.97 (1.25-3.09) 0.003 31
Minor bleeding 8 60,414 2080 38,518 663 21,896 1.63 (1.49-1.77) <0.001 21 0.035
low dose 5 32,750 984 16,571 566 16,179 1.66 (1.50-1.83) <0.001 0
Standard dose 6 38,494 1037 19,269 657 19,225 1.77 (1.43-2.19) <0.001 56
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proportionally as the concentration of NoaCs 
increases. if more thrombin is generated, the lev-
el of free (active) thrombin will increase at any 
given concentration of NoaCs. Thus, if there are 
sufficiently strong procoagulant stimulus, the in-
hibitory effect could be overcome.28 This might 
be the reason why a lower incidence of intracra-
nial bleeding was reported with some NoaCs 
than VKas in several studies.29-31 However, the 
overall clinical effect of this property seems to be 
difficult to predict.28
in our analysis, NoaCs decreased all-cause 
mortality even though they increased major 
bleeding. Similarly, the effects of NoaCs on 
secondary endpoints showed both favourable 
and unfavourable results. effects of NoaC on 
bleeding seems to be dose-dependent, accord-
ing to the subgroup analysis of low dose versus 
standard dose in major bleeding and intracranial 
haemorrhage. When comparing low dose No-
aCs versus standard dose NoaCs we found that 
low doses were associated with reduced mortal-
ity, reduced major bleeding, and stroke. Using a 
low dose of NoaCs in these setting seems rea-
sonable according to the finding of this study but 
considering that there is still debate about dos-
ing in other settings,32-34 we could not conclude 
which dosage is beneficial. Maybe there shall be 
a “goldilocks” dose which won’t increase the 
risk of bleeding, although still reduces mortality. 
or there may be a need for different doses for a 
different population (i.e., standard dose NoaC 
for aMi patients and low dose for other patients).
We did not want to include a comparison of 
warfarin with NoaCs, because warfarin was 
used almost exclusively in atrial fibrillation 
which was not included in our current research. 
However, warfarin might have a role in Cad or 
Pad, like NoaCs, and may have some advan-
tages compared to NoaCs. The beneficial ef-
fects of warfarin in cardiovascular disease were 
previously reported.35-37 also, it has cheap, easy 
to get, well-known antidotes (vitamin K, fresh 
frozen plasma and coagulation factors concen-
trates). in contrast, the antidotes for NoaCs are 
not available, recently approved, or very expen-
sive.38-40 When bleeding occurs, the availability 
of an antidote may be important to the outcome.
in conclusion, NoaCs reduced all-cause mor-
which included patients similar to those of our 
meta-analysis was limited to only one NoaC 
agent (four trials on rivaroxaban were includ-
ed).12 as far as we know, our study is the first 
which encompasses all the NoaCs into the anal-
ysis. We included all the studies performed over 
more than ten years, gathered all the reports on 
all marketed NoaCs, even including sensitivity 
analyses with those which are currently not on 
the market and had results showing similar mag-
nitude and direction that the main analyses (Sup-
plementary digital Material 10: Supplementary 
Table V). Studies with out of market NoaCs are 
indicated in the Supplementary digital Material 
2.
all the studies we included (66,665 patients 
overall) were high-quality rCTs, and at low risk 
of bias. Previous meta-analyses of NoaCs usu-
ally included only patients with atrial fibrillation 
or venous thromboembolism (VTe), or belong-
ing to a specific age population.7, 25-27 Cohen et 
al. performed a systematic review and meta-
analysis of NoaCs in VTe, reporting that the 
risk of VTe or VTe-related death was lower in 
NoaCs and warfarin iNr 2.0-3.0 when com-
pared with aspirin.25 Hulle et al. also compared 
NoaCs with VKas in VTe and concluded that 
the efficacy of NoaCs was comparable to VKa 
and that the risk of bleeding complication was 
reduced.26 Zelniker et al. compared NoaCs with 
warfarin in patients with atrial fibrillation, to find 
out if there was effect modification by Cad sta-
tus.7 The effect of NoaCs was beneficial com-
pared to warfarin and was not different by the 
presence or absence of the Cad. Sardar et al. 
compared NoaCs with conventional treatment 
(Warfarin, aspirin, enoxaparin, VKa, or place-
bo) in patients aged 75 and older with various 
diseases, and reported that NoaCs did not cause 
excessive bleeding and were associated with 
equal or greater efficacy than conventional treat-
ment.27
These favourable results of NoaCs might be 
caused by possible merits over other anticoagu-
lants. First, NoaCs target specific factors in the 
coagulation cascade (either factor Xa or throm-
bin), unlike warfarin and VKas.28 Second, No-
aCs do not completely inhibit the target protease. 
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tality in patients with or at risk for Cad or Pad, 
even though it increased the risk of major bleed-
ing. Future study regarding the best doses of No-
aCs is warranted.
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